JP2023500492A5 - - Google Patents
Info
- Publication number
- JP2023500492A5 JP2023500492A5 JP2022525520A JP2022525520A JP2023500492A5 JP 2023500492 A5 JP2023500492 A5 JP 2023500492A5 JP 2022525520 A JP2022525520 A JP 2022525520A JP 2022525520 A JP2022525520 A JP 2022525520A JP 2023500492 A5 JP2023500492 A5 JP 2023500492A5
- Authority
- JP
- Japan
- Prior art keywords
- abnormal
- pharmaceutical composition
- mucus
- composition according
- muc5ac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025174754A JP2026012782A (ja) | 2019-11-04 | 2025-10-16 | Ｉｌ－３３アンタゴニストの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206984.7 | 2019-11-04 | ||
| EP19206984 | 2019-11-04 | ||
| PCT/EP2020/080841 WO2021089563A1 (en) | 2019-11-04 | 2020-11-03 | Methods of using il-33 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025174754A Division JP2026012782A (ja) | 2019-11-04 | 2025-10-16 | Ｉｌ－３３アンタゴニストの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500492A JP2023500492A (ja) | 2023-01-06 |
| JP2023500492A5 true JP2023500492A5 (cg-RX-API-DMAC10.html) | 2023-09-27 |
| JP7843701B2 JP7843701B2 (ja) | 2026-04-10 |
Family
ID=68426347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525520A Active JP7843701B2 (ja) | 2019-11-04 | 2020-11-03 | Ｉｌ－３３アンタゴニストの使用方法 |
| JP2025174754A Pending JP2026012782A (ja) | 2019-11-04 | 2025-10-16 | Ｉｌ－３３アンタゴニストの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025174754A Pending JP2026012782A (ja) | 2019-11-04 | 2025-10-16 | Ｉｌ－３３アンタゴニストの使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220380450A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4054711A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7843701B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220093334A (cg-RX-API-DMAC10.html) |
| CN (2) | CN122140920A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2020379171B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3158323A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL292443A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202134261A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021089563A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991847T3 (es) | 2021-08-27 | 2024-12-05 | Medimmune Ltd | Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| TW202423972A (zh) | 2022-08-26 | 2024-06-16 | 英商梅迪繆思有限公司 | 使用抗介白素－３３抗體的氣喘治療 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2008137552A2 (en) | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| WO2015032932A1 (en) * | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
| HUE064292T2 (hu) | 2013-12-26 | 2024-03-28 | Mitsubishi Tanabe Pharma Corp | Humán anti-IL-33 semlegesítõ monoklonális antitest |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| MX387295B (es) * | 2015-03-31 | 2025-03-18 | Medimmune Ltd | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| WO2018204598A1 (en) | 2017-05-03 | 2018-11-08 | The University Of North Carolina At Chapel Hill | Methods for diagnosing or predicting chronic bronchitis |
-
2020
- 2020-11-03 JP JP2022525520A patent/JP7843701B2/ja active Active
- 2020-11-03 EP EP20797530.1A patent/EP4054711A1/en active Pending
- 2020-11-03 IL IL292443A patent/IL292443A/en unknown
- 2020-11-03 US US17/755,605 patent/US20220380450A1/en active Pending
- 2020-11-03 AU AU2020379171A patent/AU2020379171B2/en active Active
- 2020-11-03 KR KR1020227018052A patent/KR20220093334A/ko not_active Ceased
- 2020-11-03 TW TW109138235A patent/TW202134261A/zh unknown
- 2020-11-03 CA CA3158323A patent/CA3158323A1/en active Pending
- 2020-11-03 WO PCT/EP2020/080841 patent/WO2021089563A1/en not_active Ceased
- 2020-11-03 CN CN202610224570.1A patent/CN122140920A/zh active Pending
- 2020-11-03 CN CN202080076133.0A patent/CN114901361A/zh active Pending
-
2025
- 2025-08-08 AU AU2025213676A patent/AU2025213676A1/en active Pending
- 2025-10-16 JP JP2025174754A patent/JP2026012782A/ja active Pending